PT-262

• Description :

  PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity[1][2].

• UNSPSC :

  12352005

• Target :

  Apoptosis; CDK; ERK; ROCK

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pt-262.html

• Concentration :

  10mM

• Purity :

  99.21

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C(N1CCCCC1)=C2Cl)C3=C(N=CC=C3)C2=O

• Molecular Formula :

  C14H13ClN2O2

• Molecular Weight :

  276.72

• References & Citations :

  [1]Tzu-Sheng Hsu, et al. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway. Cancer Chemother Pharmacol. 2008 Oct;62 (5) :799-808.|[2]Chih-Chien Tsai, et al. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. Biochem Pharmacol. 2011 Apr 1;81 (7) :856-65.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK2; ERK; ROCK

• CAS Number :

  [86811-36-1]